TY - JOUR
T1 - In situ cytokines (IL-4, IL-10, IL-12, IFN-γ) and chemokines (MCP-1, MIP-1α) gene expression in human Leishmania (Leishmania) mexicana infection
AU - Valencia-Pacheco, Guillermo
AU - Loría-Cervera, Elsy Nalleli
AU - Sosa-Bibiano, Erika Ivett
AU - Canché-Pool, Elsy B.
AU - Vargas-Gonzalez, Alberto
AU - Melby, Peter C.
AU - Andrade-Narvaez, Fernando J.
N1 - Funding Information:
We are grateful to MSc Nicole R. Van Wynsberghe for editing and to the personnel from Secretaría de Salud (SSA) and Instituto Mexicano del Seguro Social (IMSS) Oportunidades for their valuable collaboration. This work was supported by CONACYT ID 3063P-M.
PY - 2014/9
Y1 - 2014/9
N2 - Crucial to the defense against Leishmania is the ability of the host to mount a cell-mediated immune response capable of controlling and/or eliminating the parasite. The composition of the cell populations recruited in the early phase of the infection seems to be essential for defining the infection outcomes. The signals that initiate and regulate the early immune response and local accumulation of cell subsets in the skin are poorly understood. We previously studied the in situ expression of cytokine genes in patients with localized cutaneous leishmaniasis (LCL) caused by Leishmania ( Leishmania) mexicana. In the present study we examined in situ cytokine (IL-4, IL-10, IL-12, IFN-γ) and chemokine (MCP-1, MIP-1α) gene expression in L. ( L.) mexicana active LCL lesions, and in the delayed type hypersensitivity (DTH) skin response to Leishmania antigen in subjects with healed lesion and subclinical infection. Data regarding cytokines were similar to previous studies in patients with active LCL. There were no significant differences in the profile of cytokine and chemokine gene expression in DTH from subjects with healed or subclinical infection. IL-12 gene expression detected in both groups was similar. High expression of MCP-1 was detected in all patients with active LCL. There was no difference in the level of MCP-1 expression between the healed lesion and the subclinical infection groups ( p= 0.876). IL-12 and MCP-1 in the absence of IFN-γ might be playing a crucial role in infection outcomes at skin level.
AB - Crucial to the defense against Leishmania is the ability of the host to mount a cell-mediated immune response capable of controlling and/or eliminating the parasite. The composition of the cell populations recruited in the early phase of the infection seems to be essential for defining the infection outcomes. The signals that initiate and regulate the early immune response and local accumulation of cell subsets in the skin are poorly understood. We previously studied the in situ expression of cytokine genes in patients with localized cutaneous leishmaniasis (LCL) caused by Leishmania ( Leishmania) mexicana. In the present study we examined in situ cytokine (IL-4, IL-10, IL-12, IFN-γ) and chemokine (MCP-1, MIP-1α) gene expression in L. ( L.) mexicana active LCL lesions, and in the delayed type hypersensitivity (DTH) skin response to Leishmania antigen in subjects with healed lesion and subclinical infection. Data regarding cytokines were similar to previous studies in patients with active LCL. There were no significant differences in the profile of cytokine and chemokine gene expression in DTH from subjects with healed or subclinical infection. IL-12 gene expression detected in both groups was similar. High expression of MCP-1 was detected in all patients with active LCL. There was no difference in the level of MCP-1 expression between the healed lesion and the subclinical infection groups ( p= 0.876). IL-12 and MCP-1 in the absence of IFN-γ might be playing a crucial role in infection outcomes at skin level.
KW - Chemokines
KW - Cytokines
KW - In situ
KW - Leishmania mexicana
KW - Localized cutaneous leishmaniasis
UR - http://www.scopus.com/inward/record.url?scp=84901986615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901986615&partnerID=8YFLogxK
U2 - 10.1016/j.cyto.2014.05.016
DO - 10.1016/j.cyto.2014.05.016
M3 - Article
C2 - 25022962
AN - SCOPUS:84901986615
SN - 1043-4666
VL - 69
SP - 56
EP - 61
JO - Cytokine
JF - Cytokine
IS - 1
ER -